Fusion Pharmaceuticals Profit Margin

Fusion Pharmaceuticals (FUSN) currently reports a profit margin of -292.29% as of March 2024. That compares with -10176.33% in the prior-year period — up 97.1% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Fusion Pharmaceuticals's profit margin history and peer comparisons.

Fusion Pharmaceuticals's profit margin increased from -10176.33% to -292.29% — a 97.1% year-over-year increase (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Fusion Pharmaceuticals's profit margin of -292.29% is lower than the Healthcare sector average of 15.58%. That is roughly 1975.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Fusion Pharmaceuticals's current -292.29% should be judged against Healthcare norms (sector average: 15.58%) and against FUSN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -292.29%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Fusion Pharmaceuticals, and consider following FUSN for alerts when major investors trade the stock.